Navigation Links
Rogue bacteria involved in both heart disease and infertility
Date:11/20/2007

Outside the laboratory, Anthony Azenabor is outgoing and talkative, an extrovert who laughs heartily at his own jokes.

But engrossed in his research, Azenabor is a shrewd and serious investigator who coaxes rogue bacteria to give up deadly secrets of how they cause several human illnesses.

Educated in Nigeria and Great Britain, Azenabor landed a fellowship sponsored by the World Health Organization soon after completing his doctorate on the bacteria Chlamydia. He was one of only two chosen worldwide.

Now an associate professor of health sciences at UW-Milwaukee, he has identified how two different kinds of Chlamydia can cause both coronary artery disease and miscarriages.

Solving one mystery gave him clues that he needed to figure out the other.

By focusing on the immune system mechanisms in Chlamydia infections, Azenabor has identified an important link in seemingly unrelated health problems.

The result could be new treatments and prevention strategies for both heart disease and infertility.

The first mystery

Chlamydia pneumoniae is a microbe that normally causes pneumonia and bronchitis, but it has long been associated with atherosclerosis, a cardiovascular disease also called hardening of the arteries.

It was a frightening prospect, says Azenabor, that atherosclerosis could come from a bacterial infection. He decided to look for an explanation.

Chlamydiae are unusual, says the Nigerian-born scientist, because, unlike most other bacteria, they use the same form of cholesterol for metabolism that human cells use. Chlamydiae also are intracellular pathogens, meaning that they can only grow and reproduce inside of another cell.

But these bacteria have another peculiar ability.

Normally, when a pathogen invades human tissue, the immune response unleashes killer cells called macrophages, which stretch to engulf the attacker and destroy it with toxin-producing enzymes.

Chlamydiae fight back, says Azenabor, His work shows that, as they are ingested, these two species of Chlamydia can manipulate the functions of protective cells like macrophages in creative ways.

Cholesterol connection

One of the keys lies in the macrophages cell walls, which store cholesterol and usually tightly control it.

But when its infected with C. pneumoniae, the microbe traffics cholesterol from the macrophage cell membrane to its own, causing a change in the macrophage that makes it rigid and unable to move.

The bacterium also disturbs the macrophages production of toxins in a process that transforms them into signaling molecules, which support functions that keep the bacterium alive.

C. pneumoniae really wants to hijack the cell functions for its own use, like a parasite would, he says. The macrophage, though, wants to kill Chlamydia, but its killing ability has been converted to signaling.

This is the reason the infection becomes chronic, Azenabor says. Because of signaling, everything else in the human cell is still fine except for the altered toxins, so the bacteria can reproduce in a short time.

As the macrophages become immobile, they accumulate in the blood vessel walls, setting the stage for atherosclerosis.

Infection and pregnancy

Armed with new information about how C. pneumoniae sabotages the immune response, Azenabor, who had also been studying the effects of estrogen on macrophages, turned his attention to another Chlamydia-related puzzle.

How is Chlamydia trachomatis, the species that causes a sexually transmitted disease, involved in the occurrence of spontaneous abortions or miscarriages?

He was immediately drawn to the protective cells in the placenta during early pregnancy the trophoblasts.

Its not for nothing that trophoblasts are the early cells, says Azenabor. They prevent any kind of infection that could threaten the fertilized egg. They produce toxic chemicals similar to those of macrophages.

Trophoblasts act like macrophages in many ways, and their functions are mediated by the hormones estrogen and progesterone. And cholesterol is the molecule used to produce those hormones.

Azenabors research shows that, like its cousin, C. trachomatis does take cholesterol from the trophoblast, and it also reproduces once inside the cell.

Its the same old story, says Azenabor. Only this time the attacked cell is a trophoblast instead of a macrophage, and the depleted cholesterol hinders production of estrogen and progesterone instead of altering toxin production.

Azenabors lab members are continuing their inquiry, and they then will need to test the theories with live animals.

But the scientist is optimistic. Already he has a patented process for blocking the effects of calcium signaling for C. pneumoniae.

If we can prevent C. trachomatis from becoming chronic, we could apply this remedy to pregnancy, he says.

While conducting postdoctoral work at McMaster University in Ontario, he won the Canadian Distinguished Scientist Award in 1998, and moved to the University of Waterloo.

Azenabor joined the UWM faculty in 2001, after working as a scientist in a Chlamydia lab at UWMadison. He jumped at the chance to start his own lab at UWM. Since arriving here he has won several honors, including the Shaw Distinguished Scientist Award from the James D. and Dorothy Shaw Fund in the Greater Milwaukee Foundation.

Although he didnt plan on working with Chlamydia for this long, he is now a leading researcher in the field. One attraction, he says, is the work is unpredictable.

When you begin, he says, you never know where you are going to go.


'/>"/>

Contact: Anthony Azenabor
aazenabo@uwm.edu
414-229-5637
University of Wisconsin - Milwaukee  
Source:Eurekalert

Related medicine news :

1. Bacteria See the Light
2. Antibacterial Soap Claims Just Dont Wash
3. New viruses to treat bacterial diseases -- My enemies enemy is my friend
4. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
5. Bacteria successful in cancer treatment
6. What gives us sunburn protects crayfish against bacteria
7. Appendix isnt useless at all: Its a safe house for bacteria
8. Early Bacterial Infection May Boost Asthma Risk
9. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
10. New peptide communication factor enabling bacteria to talk to each other discovered
11. New Study Reveals MRSA Bacteria Common Among Pigs and Farm Workers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Rogue bacteria involved in both heart disease and infertility
(Date:2/19/2017)... ... February 19, 2017 , ... "At your fingertips" electronic access ... and the Delaware Health Information Network (DHIN) have partnered to improve connectivity of ... health information exchange, DHIN stores and shares real-time health data for more than ...
(Date:2/18/2017)... ... February 17, 2017 , ... Butler Mobility invited Ken Matthews ... and other Butler products. Ken was impressed with the safety and reliability of ... the product on his show. This endorsement by Ken Matthews can be heard ...
(Date:2/18/2017)... (PRWEB) , ... February 18, 2017 , ... ... today provides the latest information and contact points to easily connect elderly veterans ... care, assisted living, and elder-care funding. It also conveys material on this year's ...
(Date:2/17/2017)... ... 17, 2017 , ... Wells Pharmacy Network offers physicians WellsPx3, ... and non-controlled substances plus the ability to manage orders on their desktop or ... accept electronic prescriptions, according to the Office of the National Coordinator of Health ...
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective Action ... Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ... action (CA) and preventive action (PA)? , The methods share techniques and tools ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, Musculoskeletal, ... to grow at a CAGR of 9.4% from 2017-2022 and CAGR ... a CAGR of 9.5% from 2017 to 2027. The market is ... ... you Read on to discover how you can exploit the ...
(Date:2/17/2017)... , Feb. 17, 2017 Theravance Biopharma, ... or the "Company") today announced the presentation of ... and orally administered pan-Janus kinase (JAK) inhibitor designed ... Congress of the European Crohn,s and Colitis ... reported further data from its completed Phase 1 ...
(Date:2/17/2017)...   Risperdal lawsuits involving gynecomastia (male breast growth) ... of the atypical antipsychotic medication continue to move forward ... Common Pleas, where the state,s Risperdal docket has been ... notice posted on the Court,s website , the ... 9, 2017 at 11:00 a.m. (In Re: Risperdal Litigation, ...
Breaking Medicine Technology: